JHL Becomes Eden And Announces Denosumab Progress
Offers Phase I And III Updates On Biosimilar Rival To Amgen’s Prolia
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
You may also be interested in...
Celltrion has kicked off plans for a Phase III trial for its denosumab biosimilar rival to Prolia.
Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.